Liquidia Corporation (NASDAQ:LQDA) is one of the biotech stocks to buy according to Wall Street analysts. Earlier on June 27, BTIG adjusted its price target for Liquidia from $45 to $40 while maintaining a Buy rating. The revision followed BTIG’s attendance at the United Therapeutics Corp. (NASDAQ:UTHR) versus Liquidia ‘327 Hatch Waxman trial in Delaware earlier that week.
Although BTIG still believes Liquidia has favorable odds of prevailing against United’s ‘327 patent, the firm reduced the probability of success for Liquidia’s drug, Yutrepia, in treating pulmonary hypertension associated with interstitial lung disease (PH-ILD) to 85% from 99% to better reflect the unresolved legal risk.
A pharmacist discussing with a patient wearing a face mask, examining their eye to diagnose a macular degeneration.
Key business developments for Liquidia include preparations for the potential launch of its first internally developed commercial product, Erepia, for pulmonary arterial hypertension and PH-ILD. The company received a favorable court ruling on May 8 earlier this year, dismissing United Therapeutics’ cross-claim, which removed some legal barriers to Erepia’s potential final approval.
However, Liquidia also faces challenges. The company’s revenue for Q1 2025 was only slightly higher than the previous year, and it reported a net loss of $38.4 million for the quarter, which was an increase from the prior year’s loss. There also remains uncertainty regarding potential future legal actions from United Therapeutics, which could impact Erepia’s launch.
Liquidia Corporation is a biopharmaceutical company that develops, manufactures, and commercializes various products for unmet patient needs in the US.
READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.
This article is originally published at Insider Monkey.
